AVEO presents tivozanib Phase 2 study results at ESMO Congress

[News]

AVEO Pharmaceuticals, Inc. a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that previously reported results from its Phase 2 study evaluating tivozanib for the treatment of advanced renal cell carcinoma (RCC) were presented at the 35th European Society for Medical Oncology (ESMO) Congress in Milan, Italy.

More... (http://www.news-medical.net/news/20101011/AVEO-presents-tivozanib-Phase-2-study-results-at-ESMO-Congress.aspx)